You are here

kidney disease

Palladio bags $20 million Series B to topple a problematic kidney disease drug

Endpoints

Fri, 09/25/20 - 10:33 am

Palladio Biosciences

autosomal dominant polycystic kidney disease

Alexion Ends Rare Kidney Disease Program Following Poor Data

BioSpace

Fri, 07/31/20 - 11:06 pm

Alexion Pharmaceuticals

Reata Bags $350M As It Preps Rare Chronic Kidney Disease Drug For FDA

Xconomy

Thu, 06/11/20 - 10:42 pm

Reata Pharmaceuticals

chronic kidney disease

bardoxolone methyl

Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia

Xconomy

Thu, 06/11/20 - 10:38 pm

Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech

Xconomy

Tue, 06/2/20 - 11:09 pm

Chinook Therapeutics

Cara and Vifor's Korsuva Hits the Mark for Treating Severe Itching in Kidney Patients

BioSpace

Tue, 04/21/20 - 11:45 pm

Cara Therapeutics

Vifor Fresenius Medical Care Renal Pharma

Bayer’s big kidney disease readout approaches

EP Vantage

Tue, 04/21/20 - 12:27 pm

clinical trials

diabetic kidney disease

Lilly and Boehringer's Jardiance, chasing AZ, nabs speedy FDA review in kidney disease

Fierce Pharma

Thu, 03/12/20 - 10:57 pm

Boehringer Ingelheim

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

Biopharma Dive

Tue, 12/17/19 - 10:29 am

clincial trials

Primary Hyperoxaluria

Roche steers Gazyva into a new PhIII program after combo shows promise in lupus nephritis study

Endpoints

Mon, 11/11/19 - 11:04 am

monoclonal antibodies

clinical trials

Data From 3 Roxadustat Trials Lead Off Kidney Week Sessions Ahead of Efficacy, Safety News

Managed Markets Network

Sat, 11/9/19 - 12:12 pm

EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

Fierce Pharma

Tue, 09/17/19 - 11:00 am

Boehringer Ingelheim

FDA developing guidance on real-world data quality issues, officials say

Endpoints

Tue, 09/10/19 - 11:34 pm

real world evidence

real world data

With industry's growing kidney moment, Everest begins building kidney portfolio

BioCentury

Mon, 06/10/19 - 09:29 am

Everest Medicines

clinical trials

IgA nephropathy

J&J’s Invokana closes on diabetic kidney disease approval

Pharmaforum

Thu, 05/23/19 - 09:50 am

diabetic kidney disease

priority review

Gilead strikes deal with biotech Goldfinch Bio to tackle kidney diseases

Marketwatch

Wed, 05/8/19 - 12:37 pm

Gilead Sciences

drug development

Outracing 2 giant rivals, J&J touts promising PhIII Invokana data as a game-changer for kidney disease risks

Endpoints

Sun, 04/14/19 - 11:58 pm

Achillion Meets Enrollment Target in Kidney Disease Studies

Yahoo/Zacks.com

Thu, 04/4/19 - 12:11 pm

clinical trials

Alexion’s newly approved rare-disease drug notches another clinical trial win

Stat

Mon, 01/28/19 - 11:10 am

Alexion Pharmaceuticals

clinical trials

Release: Vascular Therapies Appoints John McDermott as Chief Executive Officer

CP Wire

Thu, 01/10/19 - 03:26 pm

Vascular Therapies

Pages